Literature DB >> 7566361

Post-ischemic administration of the acetylcholinesterase inhibitor ENA-713 prevents delayed neuronal death in the gerbil hippocampus.

K Tanaka1, K Mizukawa, N Ogawa, A Mori.   

Abstract

We examined by morphological methodology the effect of (S)-N-ethyl-3-[(1-dimethyl-amino)ethyl]-N-methyl-phenylcarbamate hydrogentartrate (ENA-713), an acetylcholinesterase (AChE) inhibitor, on ischemia-induced neuronal death in the gerbil hippocampus due to a 5-min ligation of bilateral common carotid arteries after light ether anesthesia. Pyramidal cells had been decreased to 27% of sham-operated controls and the number of hypertrophic astrocytes expressing glial fibrillary acidic protein (GFAP) markedly increased in the hippocampal CA1 subfield 14 days after ischemia. However, post-ischemic administration of ENA-713 (three times 0.2 mg/kg, i.p.) significantly ameliorated this ischemia-induced decrease in the number of pyramidal cells by 47% of sham-operated controls, furthermore, it reduced the ischemia-induced accumulation of GFAP-positive astrocyte in the CA1 region. Together with previous results showing that ENA-713 protected against the ischemia-induced cholinergic abnormalities in the gerbil brain and improved cholinergic dysfunctions in the senescent rat brain, our present findings suggest that ENA-713 prove to be useful for treatment with senile dementia such as cerebrovascular dementia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7566361     DOI: 10.1007/BF01705533

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  37 in total

Review 1.  Glial fibrillary acidic protein (GFAP): the major protein of glial intermediate filaments in differentiated astrocytes.

Authors:  L F Eng
Journal:  J Neuroimmunol       Date:  1985-06       Impact factor: 3.478

2.  The microglial reaction in the rat dorsal hippocampus following transient forebrain ischemia.

Authors:  T Morioka; A N Kalehua; W J Streit
Journal:  J Cereb Blood Flow Metab       Date:  1991-11       Impact factor: 6.200

3.  Acetylcholinesterase inhibitor ENA-713 protects against ischemia-induced decrease in pre- and postsynaptic cholinergic indices in the gerbil brain following transient ischemia.

Authors:  K Tanaka; N Ogawa; K Mizukawa; M Asanuma; Y Kondo; S Nishibayashi; A Mori
Journal:  Neurochem Res       Date:  1994-02       Impact factor: 3.996

4.  Metabolic fate of 14C-labeled glutamate in astrocytes in primary cultures.

Authors:  A C Yu; A Schousboe; L Hertz
Journal:  J Neurochem       Date:  1982-10       Impact factor: 5.372

5.  Immunocytochemical study of an early microglial activation in ischemia.

Authors:  J Gehrmann; P Bonnekoh; T Miyazawa; K A Hossmann; G W Kreutzberg
Journal:  J Cereb Blood Flow Metab       Date:  1992-03       Impact factor: 6.200

6.  Effects of dihydroergotoxine on central cholinergic neuronal systems and discrimination learning test in aged rats.

Authors:  N Ogawa; M Nomura; K Haba; M Asanuma; K Tanaka; K Hori; A Mori
Journal:  Brain Res       Date:  1992-07-24       Impact factor: 3.252

7.  Astrocytes increase in glial fibrillary acidic protein during retrograde changes of facial motor neurons.

Authors:  M B Graeber; G W Kreutzberg
Journal:  J Neurocytol       Date:  1986-06

8.  Reactive astrocytes in the kainic acid-damage hippocampus have the phenotypic features of type-2 astrocytes.

Authors:  A Represa; J Niquet; C Charriaut-Marlangue; Y Ben-Ari
Journal:  J Neurocytol       Date:  1993-04

9.  Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine.

Authors:  K L Davis; R C Mohs
Journal:  Am J Psychiatry       Date:  1982-11       Impact factor: 18.112

10.  Loss of N-methyl-D-aspartate (NMDA) receptor binding in rat hippocampal areas at the chronic stage after transient forebrain ischemia: histological and NMDA receptor binding studies.

Authors:  N Ogawa; K Haba; K Mizukawa; M Asanuma; H Hirata; A Mori
Journal:  Neurochem Res       Date:  1991-05       Impact factor: 3.996

View more
  5 in total

1.  In vivo investigations on the cholinesterase-inhibiting effects of tricyclic quinazolinimines: scopolamine-induced cognitive impairments in rats are attenuated at low dosage and reinforced at higher dosage.

Authors:  D Appenroth; M Decker; C Tränkle; K Mohr; J Lehmann; C Fleck
Journal:  Pflugers Arch       Date:  2007-08-24       Impact factor: 3.657

Review 2.  Rivastigmine. A review of its use in Alzheimer's disease.

Authors:  C M Spencer; S Noble
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 3.923

Review 3.  Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment.

Authors:  Juan Wang; Hai-Yan Zhang; Xi-Can Tang
Journal:  Acta Pharmacol Sin       Date:  2009-07       Impact factor: 6.150

4.  Proteomic analysis of neuronal hypoxia in vitro.

Authors:  K Jin; X O Mao; D A Greenberg
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

5.  Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial.

Authors:  Kyung Won Park; Eun-Joo Kim; Hyun Jeong Han; Yong S Shim; Jae C Kwon; Bon D Ku; Kee Hyung Park; Hyon-Ah Yi; Kwang K Kim; Dong Won Yang; Ho-Won Lee; Heeyoung Kang; Oh Dae Kwon; SangYun Kim; Jae-Hyeok Lee; Eun Joo Chung; Sang-Won Park; Mee Young Park; Bora Yoon; Byeong C Kim; Sang Won Seo; Seong Hye Choi
Journal:  PLoS One       Date:  2017-08-07       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.